Disparities, trends, and projections of cancer mortality burden related to high body mass index in China from 2005 to 2030.

IF 11.7 1区医学 Q1 CELL BIOLOGY

Cell Reports Medicine Pub Date : 2025-05-12 DOI:10.1016/j.xcrm.2025.102137

Yixin Tian, Xue Cao, Chenye Chang, Xin Wang, Congyi Zheng, Xuyan Pei, Xue Yu, Yujie Zhang, Nuerguli Tuerdi, Zhenping Zhao, Limin Wang, Peng Yin, Yuehui Fang, Mei Zhang, Yuna He, Maigeng Zhou, Zengwu Wang

{"title":"Disparities, trends, and projections of cancer mortality burden related to high body mass index in China from 2005 to 2030.","authors":"Yixin Tian, Xue Cao, Chenye Chang, Xin Wang, Congyi Zheng, Xuyan Pei, Xue Yu, Yujie Zhang, Nuerguli Tuerdi, Zhenping Zhao, Limin Wang, Peng Yin, Yuehui Fang, Mei Zhang, Yuna He, Maigeng Zhou, Zengwu Wang","doi":"10.1016/j.xcrm.2025.102137","DOIUrl":null,"url":null,"abstract":"High body mass index (BMI), defined as a BMI greater than or equal to 20-25 kg/m2, is considered a rapid-increased risk factor for cancer. Based on comparative risk assessment framework, we elaborate the mortality burden of cancers attributable to high BMI in China. In 2018, we estimated that there were 85.19 thousand cancer-related deaths and 2,220.01 thousand cancer-related years of life lost (YLLs) attributable to high BMI in China. Of these, 62.14 thousand deaths and 1,698.81 thousand YLLs were from males. With higher socioeconomic levels, the burden generally increases initially and then decreases. By 2030, the projected age-standardized mortality rate attributable to high BMI in China will be 6.67 per 100,000 people, increased by 3.25% from that in 2005. In summary, the swift increase and substantial disparities in the cancer burden attributable to high BMI underscore the urgent need for evidence-based policies and interventions in China.","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":" ","pages":"102137"},"PeriodicalIF":11.7000,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cell Reports Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.xcrm.2025.102137","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CELL BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

High body mass index (BMI), defined as a BMI greater than or equal to 20-25 kg/m², is considered a rapid-increased risk factor for cancer. Based on comparative risk assessment framework, we elaborate the mortality burden of cancers attributable to high BMI in China. In 2018, we estimated that there were 85.19 thousand cancer-related deaths and 2,220.01 thousand cancer-related years of life lost (YLLs) attributable to high BMI in China. Of these, 62.14 thousand deaths and 1,698.81 thousand YLLs were from males. With higher socioeconomic levels, the burden generally increases initially and then decreases. By 2030, the projected age-standardized mortality rate attributable to high BMI in China will be 6.67 per 100,000 people, increased by 3.25% from that in 2005. In summary, the swift increase and substantial disparities in the cancer burden attributable to high BMI underscore the urgent need for evidence-based policies and interventions in China.

查看原文本刊更多论文

2005 - 2030年中国高体重指数相关癌症死亡负担的差异、趋势和预测

高身体质量指数（BMI），定义为BMI大于或等于20-25 kg/m2，被认为是癌症快速增加的危险因素。基于比较风险评估框架，我们详细阐述了中国高BMI导致的癌症死亡率负担。2018年，我们估计中国因高BMI导致的癌症相关死亡人数为85.19万人，癌症相关寿命损失年（yls）为2220.01万人。其中，男性死亡621.4万人，男性死亡1698.81万人。社会经济水平越高，负担一般先增加后减少。预计到2030年，中国高BMI年龄标准化死亡率为6.67 / 10万人，比2005年提高3.25%。总之，高BMI导致的癌症负担的迅速增加和巨大差异强调了中国迫切需要循证政策和干预措施。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cell Reports Medicine Biochemistry, Genetics and Molecular Biology-Biochemistry, Genetics and Molecular Biology (all)

CiteScore

15.00

自引率

1.40%

发文量

231

审稿时长

40 days

期刊介绍： Cell Reports Medicine is an esteemed open-access journal by Cell Press that publishes groundbreaking research in translational and clinical biomedical sciences, influencing human health and medicine. Our journal ensures wide visibility and accessibility, reaching scientists and clinicians across various medical disciplines. We publish original research that spans from intriguing human biology concepts to all aspects of clinical work. We encourage submissions that introduce innovative ideas, forging new paths in clinical research and practice. We also welcome studies that provide vital information, enhancing our understanding of current standards of care in diagnosis, treatment, and prognosis. This encompasses translational studies, clinical trials (including long-term follow-ups), genomics, biomarker discovery, and technological advancements that contribute to diagnostics, treatment, and healthcare. Additionally, studies based on vertebrate model organisms are within the scope of the journal, as long as they directly relate to human health and disease.